Skip to content

G&A at other companies

NeoGenomics logo
NeoGenomicsNEO
$65.74M-3.6%
Veracyte logo
VeracyteVCYT
$23.68M-30.0%
Guardant Health logo
Guardant HealthGH
$57.93M+23.4%
Teladoc Health logo
Teladoc HealthTDOC
$102.09M-9.5%

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's G&A?
CareDx (CDNA) reported G&A of $30.48M in Q1 2026.
How has CareDx's G&A changed year-over-year?
CareDx's G&A increased by 33.9% year-over-year, from $22.77M to $30.48M.
What is the long-term trend for CareDx's G&A?
Over 4 years (2021 to 2025), CareDx's G&A has grown at a 9.4% compound annual growth rate (CAGR), from $74.96M to $107.57M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.